Industry Leaders

  1. Integrating The Digital And Physical Supply Chain In Clinical Trials 5/26/2015

    For decades, the pharmaceutical industry was characterized as risk averse, conservative, and slow to change. In such an environment, being a change agent was not often a job requirement. That’s no longer the case, as innovation outside the laboratory is valued as never before. One change ready to be explored is improving the efficiency and effectiveness of the clinical supply chain by adopting a holistic model that will minimize costs, increase agility and control, and provide greater traceability.

  2. What Big Pharma Can Do To Combat The Latest Patent Cliff 3/31/2015

    The patent cliff era is far from over for the pharma industry. In the last three years, some of the biggest drugmakers have seen their blockbuster patents expire, a trend that will only increase going forward. A recent study by GlobalData estimates the industry will lose more than $60 billion in revenue through the end of 2019 due to the patent cliff.

  3. 6 Questions To Answer Before Considering A Carve-Out 2/25/2015

    Carve-out transactions are no walk in the park. Forming an entirely new entity is extremely difficult, especially when you consider the many moving parts that have to be managed all at one time.

  4. The New Regulations: Will They Hurt Your Business? 2/1/2015

    Accurate and timely safety/ pharmacovigilance (PV) reporting is required to avoid embarrassing Warning Letters and potentially huge fines and penalties.

  5. Precision Oncology: Big Data And Analytics Come To Cancer Care 12/24/2014

    Cancer care is creating a new era of precision oncology. Profiling the molecular alterations in a patient’s tumor can identify changes that correlate with likely response or resistance to particular therapies. This type of molecular profiling also can lead to more precise treatment, replacing historical “one-size-fits-all” approaches.

  6. Approaches To Comparative Effectiveness Research 12/7/2010

    The outcomes and costs associated with medical innovations are of increasing interest. Randomized clinical trials are the standard for determining if a therapy is safe and efficacious, but may not reflect real world treatment effectiveness. The evidence gap between clinical trials and studies of effectiveness is gaining importance.

  7. Improving Global Health Through Advances In Pharmaceutical Sciences 12/7/2010

    The future success of our industry will largely depend on our ability to cooperate internationally. The face of our industry is changing, and although this may present a number of short-term challenges, the change is for the better — it does present a wealth of opportunities in areas previously underserved or in some cases not served at all.